Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan granted European approval for Ozurdex

Allergan granted European approval for Ozurdex

29th July 2010

Allergan has received marketing approval in Europe for a new treatment for macular oedema caused by retinal vein occlusion.

The company stated that Ozurdex, which will launch in the third quarter of 2010, is the first therapy of its kind, being a biodegradable intravitreal implant of dexamethasone which counteracts oedema and improves vision.

It has been approved by the European Medicines Agency based on results from the recent Geneva clinical trial, during which the treatment was shown to provide clinically significant improvements in vision when compared to placebo.

As the first and only treatment to be approved for this application, it is hoped that Ozurdex will provide a new therapy option in an area in which few are currently available.

David Endicott, president of Allergan in Europe, Africa and the Middle East, said: “We are delighted that the European Medicines Agency has granted marketing authorisation for Ozurdex.”

This comes after the company received approval from UK regulators earlier this month for the use of its drug Botox as a therapy for chronic migraine sufferers.ADNFCR-8000103-ID-800007886-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.